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THE EFFECT OF LOW INTENSITY PULSED ULTRASOUND TREATMENT
COMBINED WITH MESENCHYMAL STROMAL CELL INJECTION FOR
CARTILAGE REGENERATION IN A KNEE OSTEOCHONDRAL DEFECT
MODEL OF RATS.
S. Yamaguchi y,z, T. Aoyama y, A. Ito y,z, M. Nagai y, H. Iijima y, J. Tajino y,
X. Zhang y, W. Kiyan y, H. Kuroki y. yHuman Hlth. Sci.s, Graduate Sch. of
Med., Kyoto Univ., Kyoto, Japan; z Japan Society for the Promotion of Sci.,
Tokyo, Japan
Purpose: Once cartilage is injured, it rarely recovers spontaneously,
because of their poor intrinsic healing capacity. Cell transplantation
therapy is anticipated to regenerate cartilage defect. Mesenchymal
stromal cell (MSC) is one of expecting cell sources for cartilage repair
due to their character including the capability which differentiate into
chondrocyte. However there were few study that veriﬁed efﬁcacy and
safety of aftertreatment post cell transplantation. There were some
reports that low intensity pulsed ultrasound (LIPUS), which is used for
bone fracture treatment, could stimulate MSC differentiation into
osteo-/chondro-cyte in vitro. The aim of this study was to investigate
whether LIPUS treatment combined with cell therapy could affect car-
tilage regeneration for a knee osteochondral defect model of rats.
Methods: This study was approved by the animal research committee
of our facility. An osteochondral defect of 1mm diameter was created on
both femur grooves of twelve Wistar rats at 12-week old. Four weeks
after creation of the defect, 1.0 106 allogeneic bone marrow MSCs
diluted with phosphate-buffered saline (PBS) was transplanted into
right knee joint by intra-articular injection and PBS without MSC was
injected into left knee joint. The rats were divided into 2 interventions:
without or with LIPUS treatment. Two days after injection, the rats with
LIPUS were subjected to LIPUS treatment according to parameters
borrowed from those for bone fracture treatment, 20 min/day, 5 days/
week, to both knee joints. After 4 and 8 weeks intervention, the rats
were euthanized, femora were removed and divided into four groups:
Control group (PBS injection), LIPUS group (PBS injection with LIPUS
treatment), MSC group (MSC injection) and MSCL group (MSC injection
with LIPUS treatment). The 6-mm thick serial sections of the femur
specimen stained with safranin-O and hematoxylin-eosin were exam-
ined and scored with Wakitani’s cartilage repair score. The collagen
type I and II expressions were also observed by immunohistochemical
methods.
Results: Four weeks after intra-articular injection, the histological score
were as follows, Control group: 8.7±2.36, LIPUS group: 4.7±1.31, MSC
group: 4.7±1.31, MSCL group: 4.3±0.65. The defect area was ﬁlled with
repair tissue which wasn’t hyaline cartilage in Control group. Repair
tissue in Control group was mostly expressed by collagen type I, but
collagen type II expression was restricted in deep zone. In LIPUS, MSC
andMSCL group, repair tissue mostly included hyaline cartilage like cell
morphology, and showed SO staining intensity in middle zone. The
repair tissue in these three group was thicker than Control group. The
expression of collagen type II was observed in wide range of repair
tissue in LIPUS, MSC and MSCL group, but the expression of type I
collagen was observed through surface and middle zone in these
groups. Eight weeks after intra-articular injection, the histological score
were as follows, Control group: 7.7±2.36, LIPUS group: 7.0±1.96, MSC
group: 4.7±1.31, MSCL group: 4.0±0.00. In Control and LIPUS group,
ﬁbroblast like cell morphology was observed and SO intensity was
reduced. The expression of collagen type II was attenuated through
surface to middle zone in Control group, while attenuated in surface
zone of LIPUS group. In MSC and MSCL group, hyaline cartilage like cell
morphology was observed in repair tissue, but the SO intensity was
reduced. The expression of collagen type II was attenuated in surface
zone of MSC and MSCL group. The expression of collagen type I was
located in surface zone of all group or middle zone in some specimen.
Conclusions: It might be indicated LIPUS treatment or MSC injection
could stimulate cartilage regeneration in 4 weeks after MSC injection,
but repaired cartilage stimulated by LIPUS treatment was deteriorated
in 8 weeks after MSC injection. In this experiment condition there
might be little interactive effect between LIPUS and MSC injection for
cartilage repair.214
THE EFFECT OF SYSTEMIC ADMINISTRATION OF GRANULOCYTE-
COLONY STIMULATING FACTOR (G-CSF) ON FULL THICKNESS
CARTILAGE DEFECT IN A RABBIT
T. Sasaki, T. Sasho, S. Yamaguchi, Y. Akatsu, J. Katsuragi, T. Fukawa,
J. Endo, H. Hoshi, Y. Yamamoto, K. Takahashi. Chiba Univ. Graduate Sch.
of Med., Chiba, Japan
Purpose: Bone marrow stimulation is in use clinically as a treatment
option for cartilage defects. Theoretically mesenchymal stem cells
reside in bone marrow are induced into cartilage defects followed by
cartilage repair with this technique. Although mostly good clinical
results were reported, histology revealed repaired cartilage was ﬁbro-
to hyaline-like cartilage.
The aim of this study is to investigate whether systemic administration
of G-CSF, stimulant of bone marrow, could improve the quality of
repaired tissue using full thickness articular cartilage defect model of a
rabbit.
Methods: Thirty 12week-old male New Zealand White rabbits were
divided into three groups.
The low dose group (n¼10) received daily 10mg/kg of G-CSF, the high
dose group (n¼10) 50mg/kg, subcutaneous injections for three days,
prior to creating cartilage defects. To the control group (n¼10), saline
was administered for three days.
48 hours after the ﬁrst injection, a 5.2mm diameter cylindrical osteo-
chondral defect was created in the center of the femoral trochlea.
4, 12 weeks after the procedure, status of repaired tissue was evaluated
by macroscopically as well as microscopically.
Results: Macroscopically, the defect ﬁllings and the tissue qualities
were better in G-CSF group than in the control group at 4 weeks. (High
dose group showed better than the low dose group.)
Qualities of repaired cartilage were better in the G-CSF group at 12
weeks but the defect ﬁllings were better in the control group, which
assumed to be hypertrophy of ﬁbrocartilage.
Conclusions: Macroscopically, G-CSF administration prior to bone
marrow stimulation was effective in modifying quality of repaired tis-
sue.
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INTRODUCTION OF MESSENGER RNA INTO KNEE ARTICULAR
CARTILAGES USING POLYPLEX NANOMICELLE
H. Aini y, K. Itaka z, U-i. Chung y, S. Ohba y. yDept. of Bioengineering, The
Univ. of Tokyo Graduate Sch. of Engineering, Tokyo, Japan; zDiv. of Clinical
Biotechnology, Ctr. for Disease Biology and Integrative Med., The Univ. of
Tokyo Graduate Sch. of Med., Tokyo, Japan
Purpose: Osteoarthritis (OA) is a degenerative joint disease that is
caused by an imbalance in cartilage degeneration and synthesis, which
results in pain and low quality of life in patients. It is a major health
problem in elderly generation. Besides painkillers and anti-inﬂamma-
tory drugs alleviating OA symptoms, disease-modifying osteoarthritis
drugs (DMOADs) have drawn much attention. Given the fact that gene
products stimulate chondrogenesis or break down cartilage matrix,
delivery of therapeutic genes as DMOADs to the articular cartilage is a
promising strategy for the treatment of OA. However, there are con-
cerns regarding safety and efﬁciency on the introduction of nucleic
acids in vivo. Although viral transduction shows high efﬁciency of gene
introduction, its application is limited because of strong immunoge-
nicity and toxicity. Plasmid DNA transfection has a risk of insertion into
host genome. Messenger RNA (mRNA) introduction would directly
induce the expression of therapeutic proteins in target cells without any
risk of insertion mutagenesis. A biocompatible gene carrier based on
self-assembly of a polyethylene glycol (PEG)-polyamino acid block
copolymer, polyplex nanomicelle, was recently shown to achieve in vivo
mRNA introduction by solving two major limitations for the in vivo
mRNA delivery, instability and immunogenicity of mRNA. In this study,
we examined the efﬁcacy of the polyplex nanomicelle-mediated mRNA
introduction into the articular cartilage of intact or surgically-induced
OA knees in mice, aiming to apply this strategy to the treatment of OA
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mRNA. We injected 10 ml solution of polyplex nanomicelles carrying
various amount of mRNA of luciferase or green ﬂuorescent protein
(GFP) into mouse knee joints. The luciferase mRNA expression was
visualized at different time points by the IVIS imaging system. GFP
expression was analyzed in histological sections. For mRNA intro-
duction into OA cartilages, OAwas induced by surgically transecting the
medial collateral ligament and removing the medial meniscus in knee
joints of 8-week old male C57BL/6 mice. A month after the surgery, the
development of OAwas conﬁrmed by safranin-O staining and the OARSI
scoring system. We then injected 10 ml solution of polyplex nano-
micelles carrying mRNA of interest into OA knee joints every other day
or once every 4 days for 2 weeks.
Results: In vivo imaging of luciferase activities revealed that intra-
articular injections of polyplex nanomicelles carrying luciferase mRNA
induced the production of functional luciferase proteins around the
knee joints in mice. Luciferase activities were observed at 24 hours after
injection and they were maintained for more than 4 days. When we
injected polyplex nanomicelles carrying GFP into intact and surgically-
induced OA knee joints in mice, GFP expression was observed not only
in both intact and OA cartilages, but also in the meniscus. There was no
symptom associated with immune reactions in the mRNA injected
joints.
Conclusions: These results indicate that the polyplex nanomicelle
successfully introduced exogenous mRNA into cells around joints,
supporting the therapeutic potential of this strategy in the treatment of
OA. mRNA introductionwill enable us to utilize transcription factors for
the treatment of degenerative diseases in disease stage-speciﬁc man-
ners. Thus, this is an important initial step of the development of mRNA
introduction-based therapeutic strategies for OA.
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HUMAN CARTILAGE REPAIR USING HUMAN MESENCHYMAL STEM
CELLS AND COLLAGEN SCAFFOLDS
C. Sanjurjo Rodríguez y, T. Hermida Gomez z, I. Fuentes Boquete y,
F. De Toro Santos y, F. Blanco García z, S. Díaz Prado, Sr. y. yUniversidade
da Coru~na, A Coru~na, Spain; z Instituto de Investigacion Biomedica de A
Coru~na, A Coru~na, Spain
Purpose: The purpose was to study chondrogenesis of adult human
Bone Marrow Mesenchymal Stem Cells (hBMSCs) when culture on
collagen (Col) biomaterials. Furthermore, we evaluated the usefulness
of the generated chondrogenic constructs to repair cartilage in an in
vitro lesion model.
Methods: hBMSCs were cultured during 30 days in chondrogenic
medium, with Transforming growth factor b-3 (TGFb-3), and in a con-
trol of DMEM medium on type I Col biomaterials. We have tested
growth and cell morphology on the constructs by histochemical and
Scanning (SEM) and Transmission (TEM) Electron Microscopy. Chon-
drogenic differentiation was evaluated in all the constructs by histo-
chemical and immunohistochemistry analyses and molecular biology. 3
mm lesions were made in human cartilage biopsies and were pre-
treated with 10ng/ml IL-b for 24 hours. 2x105 BMSCs were seeded on
type I Col biomaterials, introduced inside the lesion, and cultured
during 30 days in chondrogenic medium with TGFb-3. Repaired tissue
was evaluated by histochemistry and immunohistochemistry, and
macroscopically using the ICRS scale.
Results: Histology showed that hBMSCs have grown through the scaf-
folds, being the cell percentage higher than 75% in the chondrogenic
constructs. It was observed a big amount of extracellular matrix (ECM),
which showed proteoglycan and type II Col positivity in chondrogenic
but not in control constructs. By measurement of relative expression
levels (REL), type II Col and aggrecan gene expression was seen only in
cells grown in chondrogenic medium. Electron microscopy showed a
big amount of mitochondria and oval/rounded shape cells in chondro-
genic samples. In the in vitro model, histochemistry showed that after
30 days, the cells ﬁlled almost the 90% of the lesion with a cellular
density in the graft higher than the native cartilage (Fig. 1A, H-E). We
found integration of the neotissue with the border of the lesion.
Regarding the ECM of the neotissue was a mixture of hyaline- and ﬁbro-
cartilage, ﬁnding chondrocytes inside lacunas and an ECM positive for
type II Col and aggrecan (Figure 1A, COL II and AGG). In the macroscopic
ICRS assessment, the score of the repair was 21 out of 24 points (Fig. 1B).
Conclusions: Data showed that hBMSCs are able to grow on Col bio-
materials and differentiate to a chondrocityc-like phenotype. Thesechondrogenic constructs are able to repair an in vitro human cartilage
lesion after a 24-hour-pretreatment with 10ng/ml IL-b. Acknowledge-
ments: Opocrin S.P.A.; CAM (S2009/MAT-1472); CIBER-BBN; Red Gallega
de Terapia Celular, Xunta de Galicia (R2014/050); GPC, Xunta de Galicia
(GPC2014/048); Fundacion Espa~nola de Reumatología (2014 grant);
Fundacion Profesor Novoa Santos.Cell Signaling
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VIPERIN; A NOVEL CHONDROGENIC REGULATOR
M.M. Steinbusch y, M.M. Caron y, F. Eckmann z, E. Lausch z,
L.W. van Rhijn y, B. Zabel z, T.J. Welting y. yDept. of Orthopaedic Surgery,
Lab. for Experimental Orthopaedics, Maastricht Univ. Med. Ctr.,
Maastricht, Netherlands; zCtr. for Paediatrics and Adolescent Med., Univ.
of Freiburg, Freiburg, Germany
Purpose: The ribonuclease mitochondrial RNA processing (RMRP) gene
encodes the RNA component of a multi-protein-RNA complex called
RNase MRP. Mutations in the RMRP gene cause Cartilage Hair Hypo-
plasia (CHH). The main phenotypic hallmark of CHH is dwarﬁsm, pre-
sumably caused by impaired growth plate development. Our
preliminary data indeed show that RMRP is involved in chondrogenic
differentiation; however, it is unclear via which mechanism. Viperin is
an antiviral protein, located in the endoplasmic reticulum (ER; location
of protein synthesis and secretion), and its mRNA is a known substrate
of RNase MRP cleavage activity. As such, viperin expression has shown
to be increased in CHH patient cells and during knockdown (KD, RNAi)
of RNaseMRP subunits, including RMRP RNA itself. As the chondrogenic
function of RMRP is unclear and it is not known howmutations in RMRP
cause CHH, we hypothesize that viperin functions as a chondrogenic
regulator downstream of RNase MRP.
Methods: To investigate the expression of viperin during chon-
drogenic differentiation in vivo, viperin was detected in day 1
mouse growth plates by immunohistochemistry. Expression of
viperin mRNA and protein was determined by RT-qPCR / Western
blot in chondrogenically differentiating ATDC5 cells in the pres-
ence or absence of 1 nM bone morphogenic protein (BMP)-2 or -7.
KD of viperin expression was achieved via RNAi and protein
secretion was measured upon transfection of a secretable CMV-
Gaussia Luciferase.
Results: To investigate whether viperin plays a role in developing
chondrocytes in vivo, day 1 mouse growth plates were stained for
viperin. Profound viperin staining was detected in hypertrophic
chondrocytes. However, viperin was also expressed in a sub-
population of proliferative chondrocytes. In these cells a perinuclear
staining could be observed, which is in agreement with the local-
ization of viperin in the ER. To determine the role of viperin
expression in more detail, viperin gene expression dynamics were
determined during chondrogenic differentiation of ATDC5 cells.
Expression of viperin mRNA and protein was ﬁrst detected at day 4 in
